These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 14872465)

  • 21. Monitoring clinical trials. Caution may be warranted in releasing interim trial data.
    Thornton H
    BMJ; 2001 Dec; 323(7326):1424-5. PubMed ID: 11778589
    [No Abstract]   [Full Text] [Related]  

  • 22. Statistical issues in interpreting clinical trials.
    DeMets DL
    J Intern Med; 2004 May; 255(5):529-37. PubMed ID: 15078496
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Should contemporary rheumatoid arthritis clinical trials be more like standard patient care and vice versa?
    Pincus T; Sokka T
    Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii32-ii39. PubMed ID: 15479869
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Are clinical trials in rheumatoid arthritis generalizable to routine practice? A re-evaluation of trial entry criteria.
    Kingsley GH; Khoshaba B; Smith CM; Choy EH; Scott DL
    Rheumatology (Oxford); 2005 May; 44(5):629-32. PubMed ID: 15705630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Electronic alerts versus on-demand decision support to improve dyslipidemia treatment: a cluster randomized controlled trial.
    van Wyk JT; van Wijk MA; Sturkenboom MC; Mosseveld M; Moorman PW; van der Lei J
    Circulation; 2008 Jan; 117(3):371-8. PubMed ID: 18172036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Counterpoint: alternative trial designs for antifungal drugs--time to talk.
    Powers JH
    Clin Infect Dis; 2001 Jul; 33(1):107-9. PubMed ID: 11389502
    [No Abstract]   [Full Text] [Related]  

  • 27. The Take Control of Your Blood pressure (TCYB) study: study design and methodology.
    Bosworth HB; Olsen MK; Dudley T; Orr M; Neary A; Harrelson M; Adams M; Svetkey LP; Dolor RJ; Oddone EZ
    Contemp Clin Trials; 2007 Jan; 28(1):33-47. PubMed ID: 16996808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Various randomized designs can be used to evaluate medical tests.
    Lijmer JG; Bossuyt PM
    J Clin Epidemiol; 2009 Apr; 62(4):364-73. PubMed ID: 18945590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blinding protocols, treatment credibility, and expectancy: methodologic issues in clinical trials of osteopathic manipulative treatment.
    Licciardone JC; Russo DP
    J Am Osteopath Assoc; 2006 Aug; 106(8):457-63. PubMed ID: 16943515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pragmatic clinical trials.
    Macpherson H
    Complement Ther Med; 2004; 12(2-3):136-40. PubMed ID: 15561524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient decision aids to support clinical decision making: evaluating the decision or the outcomes of the decision.
    McCaffery K; Irwig L; Bossuyt P
    Med Decis Making; 2007; 27(5):619-25. PubMed ID: 17873254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
    Vaucher P
    Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical trial design issues: at least 10 things you should look for in clinical trials.
    Glasser SP; Howard G
    J Clin Pharmacol; 2006 Oct; 46(10):1106-15. PubMed ID: 16988199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Should subgroup analysis of randomized clinical trials have a direct impact on clinical practice?
    Bria E; Di Maio M; Cuppone F; Nisticò C; Cognetti F; Giannarelli D
    J Clin Oncol; 2007 Feb; 25(5):605-6; author reply 606-7. PubMed ID: 17290074
    [No Abstract]   [Full Text] [Related]  

  • 35. Issues in evaluating health websites in an Internet-based randomized controlled trial.
    Eysenbach G
    J Med Internet Res; 2002 Dec; 4(3):E17. PubMed ID: 12554548
    [No Abstract]   [Full Text] [Related]  

  • 36. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis.
    Strand V; Cohen S; Crawford B; Smolen JS; Scott DL;
    Rheumatology (Oxford); 2004 May; 43(5):640-7. PubMed ID: 15039493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. (Cost)-effectiveness of case-management by district nurses among primary informal caregivers of older adults with dementia symptoms and the older adults who receive informal care: design of a randomized controlled trial [ISCRTN83135728].
    Jansen AP; van Hout HP; van Marwijk HW; Nijpels G; de Bruijne MC; Bosmans JE; Pot AM; Stalman WA
    BMC Public Health; 2005 Dec; 5():133. PubMed ID: 16343336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating biologic agents in rheumatoid arthritis: a framework for clinical trials.
    Strand V; Scott DL; Panayi GS
    J Rheumatol; 1994 Aug; 21(8):1390-2. PubMed ID: 7983635
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.